U.S. markets closed

Sage Therapeutics, Inc. (SAGE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
50.00-0.27 (-0.54%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close50.27
Bid49.99 x 1200
Ask56.97 x 800
Day's Range49.42 - 50.97
52 Week Range25.01 - 173.76
Avg. Volume801,329
Market Cap2.599B
Beta (5Y Monthly)2.67
PE Ratio (TTM)N/A
EPS (TTM)-11.80
Earnings DateNov 10, 2020 - Nov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est75.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Sage Therapeutics Inc (SAGE) Q2 2020 Earnings Call Transcript
    Motley Fool

    Sage Therapeutics Inc (SAGE) Q2 2020 Earnings Call Transcript

    SAGE earnings call for the period ending June 30, 2020.

  • Benzinga

    Recap: Sage Therapeutics Q2 Earnings

    Shares of Sage Therapeutics (NASDAQ:SAGE) were flat in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 36.59% over the past year to ($2.08), which beat the estimate of ($2.66).Revenue of $1,089,000 rose by 24.74% from the same period last year, which beat the estimate of $890,000.Guidance Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: Aug 10, 2020View more earnings on SAGETime: 08:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/kkevgsu3Recent Stock Performance 52-week high: $174.73Company's 52-week low was at $25.01Price action over last quarter: Up 30.05%Company Description Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.See more from Benzinga * Earnings Scheduled For August 10, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Have Insiders Been Buying Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares?
    Simply Wall St.

    Have Insiders Been Buying Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...